Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 10;16(10):e71232.
doi: 10.7759/cureus.71232. eCollection 2024 Oct.

Bilastine Reimagined: A Comprehensive Exploration of Pruritus Management With a Novel Antihistamine

B B Mahajan  1 , Pravin Banodkar  2 , Gaurav Bhardwaj  3 , Narendra Gokhale  4 , K C Nischal  5 , S K Shahirar Ahmed  6 , Akhilesh Sharma  7 , Mayur Mayabhate  7 , Tejashri A Jaju  7
Affiliations
Review

Bilastine Reimagined: A Comprehensive Exploration of Pruritus Management With a Novel Antihistamine

B B Mahajan et al. Cureus. .

Abstract

Managing pruritic conditions is essential due to their significant impact on patients' quality of life. Chronic urticaria (CU), characterized by persistent itching and hives, severely affects daily activities and sleep. CU includes chronic inducible urticaria and chronic spontaneous urticaria, with the latter lacking identifiable triggers, making treatment especially challenging. CU is a condition that occurs across all age groups, with a higher prevalence among young adults and middle-aged women. Current antihistamine treatments include first-generation antihistamines, which are associated with sedation, and second-generation antihistamines such as cetirizine and fexofenadine, which cause less sedation but have varying efficacy and safety profiles. Bilastine, a novel second-generation H1-antihistamine, offers advantages due to its potent antihistaminic activity, rapid onset of action, and minimal sedation. This narrative review thoroughly synthesizes the evidence for the efficacy and safety of bilastine in treating CU and other pruritic conditions. By analyzing clinical trials, real-world evidence, and comparative studies, this review aims to provide a comprehensive understanding of the role of bilastine in managing pruritic conditions, emphasizing its pharmacokinetic properties, clinical efficacy, and safety profile compared to other antihistamines.

Keywords: bilastine; chronic urticaria; histamine h1 receptor; pharmacokinetics; pruritus; wheal and flare response.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

    1. Pathophysiology and treatment of pruritus in elderly. Chung BY, Um JY, Kim JC, Kang SY, Park CW, Kim HO. Int J Mol Sci. 2020;22:174. - PMC - PubMed
    1. Management of pediatric chronic spontaneous urticaria: a review of current evidence and guidelines. Chang J, Cattelan L, Ben-Shoshan M, Le M, Netchiporouk E. J Asthma Allergy. 2021;14:187–199. - PMC - PubMed
    1. Comorbidities of chronic urticaria: a glimpse into a complex relationship. Papapostolou N, Xepapadaki P, Katoulis A, Makris M. Front Allergy. 2022;3:1008145. - PMC - PubMed
    1. Diagnosis and management of urticaria in Indian settings: skin allergy Research Society’s guideline-2022. Godse K, Patil A, De A, et al. Indian J Dermatol. 2022;67:732–743. - PMC - PubMed
    1. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Church MK, Maurer M, Simons FE, et al. Allergy. 2010;65:459–466. - PubMed

LinkOut - more resources